Episode Details
Back to Episodes
222: Private equity in autism care, a watershed FDA approval, & the future of ALS treatment
Published 4 years, 2 months ago
Description
First, STAT's Tara Bannow joins us to discuss how private equity's mounting interest in autism care has created an untenable situation for many parents in the U.S. We also explain the implications of Bluebird Bio's long-awaited FDA approval, a controversial treatment for ALS, and the ups and downs of Merck's reported interest in buying Seagen.